News

The technology complements MorphoSys’s existing production platforms. It could offer advantages with regard to the production of novel antigens, which have proven difficult to produce with conventional expression

Matthew Schissler, co-founder and CEO of CBAI, said: “This is another very important step forward for Cord Blood America. “As a direct result of processing and storing cord

The phase 2/3 trial uses an adaptive-design in which the phase 2 portion enrolled 180 patients with acute cellulitis or wound infections into one of the three arms:

The Intercept device is the FDA-cleared in vitro diagnostic laboratory-based oral fluid testing system used for detecting commonly abused drugs such as marijuana, cocaine, opiates, PCP and amphetamines

Reportedly, the randomised, double-blind, placebo-controlled, multi-centered study is expected to evaluate the safety, tolerability, and efficacy of Oramed’s oral insulin delivery technology. The company is conducting the study

Per Walday, CEO of PCI Biotech, said: “We are very excited by the positive results that have been reported from University College Hospital (UCH) in London. The strong

The company sold the assets of the business, which includes manufacturing facilities in Freehold and Irvington, New Jersey, to International Vitamin Corporation, and affiliates, for a total price

The study evaluated the safety, tolerability, and pharmacokinetics of repeated doses of intravenously administered antibody in 24 rheumatoid arthritis patients with an inadequate treatment response to methotrexate. The

The company said that in cat allergy trial 210 patients are expected to be randomised to receive placebo or one of two regimes of the company’s T-cell vaccine.